Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Spanlecortemlocel - Dianthus Therapeutics

Next Previous
Search
Drug Profile

Spanlecortemlocel - Dianthus Therapeutics

Alternative Names: Cord blood stem cell therapy - Novartis; Expanded umbilical cord blood - Novartis; HSC-835; LFU835 expanded umbilical cord blood stem cells; MGTA-456

Latest Information Update: 09 Oct 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Dianthus Therapeutics
  • Class Antineoplastics; Haematopoietic stem cells therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Haematological malignancies; Inborn error metabolic disorders

Most Recent Events

  • 31 Mar 2023 Discontinued - Phase-II for Haematological malignancies in USA (IV) before March 2023
  • 31 Mar 2023 Discontinued - Phase-II for Inborn error metabolic disorders in USA (unspecified route) before March 2023
  • 03 Nov 2022 Spanlecortemlocel is still in phase-II clinical trials for haematological malignancies in USA (IV, Infusion) (NCT03674411)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top